The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
|Videos|October 3, 2017
Dr. Hofmeister on the Treatment of Patients with Newly Diagnosed Myeloma
Author(s)Craig Hofmeister, MD
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.
Advertisement
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.
Patients with multiple myeloma who are fit are usually able to treated with any available agent, says Hofmeister.
The most effective treatment is usually a 3-drug therapy of an immunomodulatory drug, a protostome inhibitor, and dexamethasone, Hofmeister adds.
Advertisement
Related to this article
MajesTEC-9 data supported an EU indication expansion for teclistamab in relapsed/refractory multiple myeloma.
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Ivonescimab Plus Chemotherapy Represents a New SOC in First-Line Biliary Tract Cancer
2
CLARITY-Gastric01 Shows OS Benefit With Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastroesophageal Carcinoma
3
Dr Chase on the Potential Role of B7-H4–Targeted ADCs in Platinum-Resistant Ovarian Cancer
4
Divarasib Improves Survival and Paves Way for New SOC in Pretreated KRAS G12C–Mutated NSCLC
5